Sumitomo Pharma (4506) Q2 2025 earnings summary

Executive summary

• Revenue increased 18.4% year-over-year to ¥180.7B, driven by strong sales of ORGOVYX®, MYFEMBREE®, and GEMTESA®, and favorable currency effects.

• Net loss improved to ¥32.2B from ¥67.7B YoY, reflecting higher revenue and reduced expenses.

• Significant cost reductions and restructuring improved core operating profit by ¥65.8B YoY, nearly breakeven.

• Strategic focus on business reconstruction, including workforce reduction and asset streamlining, to return to profitability.

• Cash and cash equivalents increased to ¥99.1B, mainly due to asset sales.

Financial highlights

• Revenue: ¥180.7B (+18.4% YoY); gross profit: ¥108.5B (+17.5% YoY).

• Core operating profit improved by ¥65.8B YoY to ¥0.0B; operating loss narrowed to ¥8.2B from ¥86.5B YoY.

• SG&A expenses decreased by 29.8% YoY; R&D expenses down 44.6%–47.8% YoY due to pipeline focus.

• Basic EPS: ¥(81.12), improved from ¥(170.51) YoY.

• Operating cash flow turned positive at ¥4.6B, up from ¥(174.5)B YoY.

Outlook and guidance

• FY2024 forecasts unchanged; full-year revenue expected at ¥338.0B (+7.5% YoY), core operating profit at ¥1.0B.

• Net loss forecast for FY2025: ¥16.0B; EPS: ¥(40.27).

• SG&A and R&D expenses projected to remain in line with Q2; asset divestitures and exchange rates could impact results.